Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: Influence of sex and age

Anna Paioli, Roberto Luksch, Franca Fagioli, Angela Tamburini, Marilena Cesari, Emanuela Palmerini, Massimo Eraldo Abate, Emanuela Marchesi, Alba Balladelli, Loredana Pratelli, Stefano Ferrari

Research output: Contribution to journalArticlepeer-review


Influence of age and sex on chemotherapy-related toxicity was evaluated in children (3-9 years), adolescents (10-17 years), and adults (up to 40 years) with localized Ewing sarcoma (ES) enrolled in the ISG/SSG III protocol. Treatment was based on vincristine, doxorubicin, cyclophosphamide, ifosfamide, dactinomycin, and etoposide. High-dose chemotherapy with busulfan and melphalan was given in poor responder patients. The analysis was based on 2191 courses of standard chemotherapy and 230 patients. A lower risk of G4 leukopenia and thrombocytopenia, hospitalization, febrile neutropenia, and red blood cell (RBC) transfusions was observed in males. Use of granulocyte colony-stimulating factor (G-CSF) was more frequent in adults, while children more often received RBC transfusions. A significant correlation between sex and chemotherapy-related toxicity was observed in the study, whereas no significant differences in terms of bone marrow toxicity can be expected according to patient age. Further studies should analyse the role of pharmacokinetics, pharmacogenomics, and clinical characteristics.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalJournal of Chemotherapy
Issue number1
Publication statusPublished - 2014


  • Age
  • Chemotherapy
  • Ewing sarcoma
  • Sex
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology


Dive into the research topics of 'Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: Influence of sex and age'. Together they form a unique fingerprint.

Cite this